WO2003090784A1 - Treatment of metabolic syndrome - Google Patents

Treatment of metabolic syndrome Download PDF

Info

Publication number
WO2003090784A1
WO2003090784A1 PCT/EP2003/004357 EP0304357W WO03090784A1 WO 2003090784 A1 WO2003090784 A1 WO 2003090784A1 EP 0304357 W EP0304357 W EP 0304357W WO 03090784 A1 WO03090784 A1 WO 03090784A1
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
growth hormone
treatment
patients
sensitising agent
Prior art date
Application number
PCT/EP2003/004357
Other languages
English (en)
French (fr)
Inventor
Bernhard Saller
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0209642A external-priority patent/GB0209642D0/en
Priority claimed from GB0218912A external-priority patent/GB0218912D0/en
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Priority to BR0309375-1A priority Critical patent/BR0309375A/pt
Priority to MXPA04010544A priority patent/MXPA04010544A/es
Priority to JP2003587413A priority patent/JP2005523915A/ja
Priority to AU2003227683A priority patent/AU2003227683A1/en
Priority to EP03725104A priority patent/EP1499357A1/en
Priority to CA002483005A priority patent/CA2483005A1/en
Priority to KR10-2004-7016843A priority patent/KR20040101545A/ko
Publication of WO2003090784A1 publication Critical patent/WO2003090784A1/en
Priority to IL16467004A priority patent/IL164670A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/EP2003/004357 2002-04-26 2003-04-24 Treatment of metabolic syndrome WO2003090784A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BR0309375-1A BR0309375A (pt) 2002-04-26 2003-04-24 Tratamento de sìndrome metabólica
MXPA04010544A MXPA04010544A (es) 2002-04-26 2003-04-24 Tratamiento del sindrome metabolico.
JP2003587413A JP2005523915A (ja) 2002-04-26 2003-04-24 代謝性症候群の処置
AU2003227683A AU2003227683A1 (en) 2002-04-26 2003-04-24 Treatment of metabolic syndrome
EP03725104A EP1499357A1 (en) 2002-04-26 2003-04-24 Treatment of metabolic syndrome
CA002483005A CA2483005A1 (en) 2002-04-26 2003-04-24 Treatment of metabolic syndrome
KR10-2004-7016843A KR20040101545A (ko) 2002-04-26 2003-04-24 대사증후군 치료
IL16467004A IL164670A0 (en) 2002-04-26 2004-10-18 Pharmaceutical compositions containing growth hormone and an insulin sensitizing agent

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0209642A GB0209642D0 (en) 2002-04-26 2002-04-26 Metabolic syndrome
GB0209642.8 2002-04-26
GB0218912.4 2002-08-14
GB0218912A GB0218912D0 (en) 2002-08-14 2002-08-14 Metabolic syndrome

Publications (1)

Publication Number Publication Date
WO2003090784A1 true WO2003090784A1 (en) 2003-11-06

Family

ID=29272006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004357 WO2003090784A1 (en) 2002-04-26 2003-04-24 Treatment of metabolic syndrome

Country Status (11)

Country Link
EP (1) EP1499357A1 (pt)
JP (1) JP2005523915A (pt)
KR (1) KR20040101545A (pt)
CN (1) CN1646167A (pt)
AU (1) AU2003227683A1 (pt)
BR (1) BR0309375A (pt)
CA (1) CA2483005A1 (pt)
IL (1) IL164670A0 (pt)
MX (1) MXPA04010544A (pt)
PL (1) PL372900A1 (pt)
WO (1) WO2003090784A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10231976B2 (en) * 2010-02-08 2019-03-19 Prairie Pharmaceuticals LLC Methods for the use of progestogen as a glucocorticoid sensitizer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M.SUGIMOTO E.A.: "Effects of troglitazone on hepatic and peripheral insulin resistance induced by growth hormone excess in rats", METABOLISM: CLINICAL AND EXPERIMENTAL, vol. 47, no. 7, 1998, pages 783 - 787, XP008019936 *
S.E.BORST E.A.: "Metformin restores responses to insulin but not to growth hormone in Sprague-Dawley rats", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 291, no. 3, 2002, pages 722 - 726, XP001162704 *

Also Published As

Publication number Publication date
MXPA04010544A (es) 2005-08-16
JP2005523915A (ja) 2005-08-11
PL372900A1 (en) 2005-08-08
KR20040101545A (ko) 2004-12-02
BR0309375A (pt) 2005-03-29
AU2003227683A1 (en) 2003-11-10
CA2483005A1 (en) 2003-11-06
CN1646167A (zh) 2005-07-27
EP1499357A1 (en) 2005-01-26
IL164670A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
EP1928499B1 (en) Use of a dpp-iv inhibitor to reduce hypoglycemic events
KR101847485B1 (ko) 초속효성 인슐린의 용도
Kokot et al. Plasma leptin concentration in kidney transplant patients during the early post-transplant period.
US6274582B1 (en) Preparation for the treatment of metabolic syndrome containing human growth hormone in combination with a cortisol synthesis inhibitor
van Thiel et al. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial
Attanasio et al. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study
Herrmann et al. Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome
JP2009539803A (ja) ソマトスタチン−アナログとドーパミン−または成長ホルモン受容体アンタゴニストの組合せ剤
CN104321074B (zh) 生长抑素类似物与11β‑羟化酶抑制剂的组合
AU2010257328A1 (en) Method of treatment using GH antagonist and somatostatin agonist
WO2003090784A1 (en) Treatment of metabolic syndrome
WO2002085406A9 (en) Methods and compositions for treating conditions associated with insulin resistance
ZA200408437B (en) Treatment of metabolic syndrome
KR101262123B1 (ko) 지질 대사 이상의 예방 또는 치료용 의약 조성물
Mehltretter et al. Long-term treatment with SMS 201–995 in resistant acromegaly: Effectiveness of high doses and continuous subcutaneous infusion
Frost et al. Growth hormone/insulin-like growth factor axis in human immunodeficiency virus-associated disease
LIN et al. An open, phase III study of lanreotide (Somatuline PR®) in the treatment of acromegaly
Reaven et al. Effect of enprostil on plasma glucose, insulin and lipid metabolism in patients with non-insulin-dependent diabetes mellitus
Inokuchi et al. Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics
VINIK et al. Familial hyperinsulinemia associated with secretion of an abnormal insulin, and coexistence of insulin resistance in the propositus
Umpierrez et al. Management of type 2 diabetes: Evolving strategies for treatment
CA3122581A1 (en) Methods for imaging and treatment of somatostatin-receptor positive tumors
WO2005021023A1 (en) Therapeutical conversion
Shelbaya et al. STUDY OF THE EFFECT OF BARIATRIC SURGERY ON SERUM GLUCAGON LIKE PEPTIDE-1 CONCENTRATION AND INSULIN RESISTANCE AMONG OBESE TYPE 2 DIABETIC PATIENTS
Ertorer et al. Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003725104

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003587413

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004/08437

Country of ref document: ZA

Ref document number: 200408437

Country of ref document: ZA

Ref document number: 1-2004-501681

Country of ref document: PH

Ref document number: 2483005

Country of ref document: CA

Ref document number: 1020047016843

Country of ref document: KR

Ref document number: 1020047016833

Country of ref document: KR

Ref document number: 20038088312

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 372900

Country of ref document: PL

Ref document number: 536041

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/010544

Country of ref document: MX

Ref document number: 2003227683

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020047016843

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1020047016833

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020047016833

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003725104

Country of ref document: EP